Ph.D., CEO, Travera
Biography
Prior to founding Travera, Dr. Reid was the founding Chairman, President and CEO of Complete Genomics (NASDAQ:GNOM), a leading developer of whole human genome DNA sequencing technologies and services. He was also Executive Chairman of Genos Research, a consumer genomics company he spun off from Complete Genomics. Prior to Complete Genomics he founded two enterprise software companies: Eloquent (NASDAQ:ELOQ), an internet video company, and Verity (NASDAQ:VRTY), an enterprise search engine company. Dr. Reid is on the Visiting Committee of the Biological Engineering Department at the Massachusetts Institute of Technology (MIT), a member of the MIT Corporation Development Committee, and an advisor to Warburg Pincus. He earned a S.B. in Physics from MIT, an MBA from the Harvard Business School, and a Ph.D. in Management Science and Engineering from Stanford University.
Clinical Dx Showcase:
Travera
Travera is developing the first universal therapy-directing biomarker for personalized medicine for cancer.
A New Approach To Personalized Medicine For Cancer
Travera has developed a new technology for identifying effective cancer drugs and drug combinations for cancer patients. Our approach uses a new measurement device invented at MIT that weighs single cells with sub-picogram accuracy, enabling us to directly measure the response of cancer cells to cancer drugs.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 22 2.30 P.M.-3.45 P.M.,Track 7 - January 23 1.15 P.M.-1.30 P.M.,Track 6 - January 24 9.00 A.M.-1.15 P.M.
The PMWC 2020 Data Applications in Clinical Diagnostics Showcase will provide a 15-minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
